Study details
Enrolling now
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
ModernaTX, Inc.
NCT IDNCT06585241ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
764
Study length
about 1.7 years
Ages
0.5+
Locations
6 sites in GA, LA, MS +2
About this study
This trial is testing a new type of vaccine against COVID-19. The goal is to see how well this vaccine works and if it's safe for adults and children.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive mRNA-1273 Variant-containing Formulation
PhasePhase 4
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: mRNA-1273.167, mRNA-1273.712, mRNA-1273.251, and mRNA-1273.261: Number of Participants with Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Study Withdrawal, and AEs of Special Interest, mRNA-1273.251 and mRNA-1273.261: Number of Participants with Unsolicited AEs
Body systems
Infectious